Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $LIVN
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/4/2024 | $65.00 | Buy | Goldman |
9/17/2024 | $55.00 → $66.00 | Neutral → Outperform | Robert W. Baird |
3/20/2024 | Buy | Needham | |
2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
9/6/2023 | $52.00 | Hold | HSBC Securities |
7/19/2023 | $56.00 | Neutral | Robert W. Baird |
4/14/2023 | $48.00 | Neutral | Mizuho |
12/21/2022 | $62.00 | Equal Weight | Barclays |
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 982570. A re
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
Results published in two articles in Brain Stimulation LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effectively demonstrated clinically meaningful therapeut
Goldman initiated coverage on LivaNova with a new price target
Goldman initiated coverage of LivaNova with a rating of Buy and set a new price target of $65.00
LivaNova upgraded by Robert W. Baird with a new price target
Robert W. Baird upgraded LivaNova from Neutral to Outperform and set a new price target of $66.00 from $55.00 previously
Needham reiterated coverage on LivaNova
Needham reiterated coverage of LivaNova with a rating of Buy
New insider Kozmina Natalia claimed no ownership of stock in the company (SEC Form 3)
3 - LivaNova PLC (0001639691) (Issuer)
Chief Legal Officer Hutchinson Michael Damon converted options into 2,254 units of Ordinary Shares and covered exercise/tax liability with 784 units of Ordinary Shares, increasing direct ownership by 64% to 3,756 units (SEC Form 4)
4 - LivaNova PLC (0001639691) (Issuer)
President, Cardiopulmonary Poletti Franco converted options into 967 units of Ordinary Shares and covered exercise/tax liability with 416 units of Ordinary Shares, increasing direct ownership by 8% to 7,218 units (SEC Form 4)
4 - LivaNova PLC (0001639691) (Issuer)
LivaNova PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - LivaNova PLC (0001639691) (Filer)
SEC Form IRANNOTICE filed by LivaNova PLC
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - LivaNova PLC (0001639691) (Filer)
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
LivaNova Appoints Susan Podlogar as a New Director
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the Board. "LivaNova's Board of Directors is pleased to welcome Susan Podlogar," said William Kozy, Chair of the Board. "Susan is a visionary leader with three decades of experience in leading business, talent, and cultural transformations at recognized global companies. She possesses a sharp understanding of the ever-changing global business landscape and will be a tremendous asset to the Board." Podlogar's career spans 30 years, holding key g
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 982570. A re
LivaNova Reports Third-Quarter 2024 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 12.3% on a constant-currency basis. Third-quarter U.S. GAAP diluted earnings per share of $0.60 and adjusted diluted earnings per share of $0.90. In October 2024, LivaNova announced the appointment of Susan Podlogar to the Board. Podlogar
LivaNova to Announce Third-Quarter 2024 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 881946. A replay will be available on
SEC Form SC 13G filed by LivaNova PLC
SC 13G - LivaNova PLC (0001639691) (Subject)
SEC Form SC 13G/A filed by LivaNova PLC (Amendment)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SEC Form SC 13G/A filed by LivaNova PLC (Amendment)
SC 13G/A - LivaNova PLC (0001639691) (Subject)